the key trials are these two
COMPASS and US retrospective study
pharmaceutical journal report
NICE guidance
other issues
https://www.amjmed.com/article/S0002-9343(15)00926-2/fulltext
risk of bleeding scores after blood clots
https://www.thrombosisresearch.com/article/S0049-3848(17)30047-6/fulltext
https://link.springer.com/article/10.1007/s10840-014-9930-y
This systematic review focused the high bleeding-risk category of commonly used risk scores in AF. Our main findings were as follows: (1) Overall HAS-BLED, HEMORR2HAGES and ATRIA are not sensitive methods to predict major bleeding; (2) HAS-BLED was the most sensitive risk score for high bleeding-risk category; and (3) HEMORR2HAGES has a high diagnostic accuracy mainly due to the high specificity, but it is not easy to use it fast.
Comments are closed.